1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Psychotic Disorders in 3 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aetiology of PD psychosis is multifactorial and likely arises from the complex interaction between dopamine replacement therapy and disease state." | 1.62 | Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset. ( Gourdon, JC; Huot, P; Kwan, C; Nuara, SG, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Nuara, SG | 2 |
| Gourdon, JC | 2 |
| Maddaford, S | 1 |
| Huot, P | 2 |
| Kwan, C | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Johnston, TH | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Brotchie, JM | 1 |
| Fox, SH | 1 |
3 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Psychotic Disorders
| Article | Year |
|---|---|
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridg | 2021 |
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2021 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |